Pharma News

...

Green shoots and cautious optimism: Insights from BIO-Europe Spring

<p>With thousands of pharma and biotech dealmakers attending last months’ BIO-Europe Spring, appetite for partnering looked alive and well.</p>

READ MORE
...

The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca | Nils Prately

<p>Despite rebellion, approval of 18.7m package opens door to likelihood of US-style executive pay elsewhereIs Pascal Soriot, the chief executive of AstraZeneca, “massively underpaid”, as the chief investment officer of Florida-based GQG Partners, one of the company’s big shareholders, argued this week? </p>

READ MORE
...

Vertex joins pharma immunotherapy deal uptick with $4.9bn Alpine purchase

Alpine’s lead asset, povetacicept, is slated to enter Phase III trials in the second half of this year.

READ MORE